PURPOSE: To assess the effectiveness of two approaches of organ-sparing treatment in @entity1 with invasive transitional cell @entity150 . @entity1 AND METHODS: During the period from June 1996 to June 2000, 33 @entity1 with invasive @entity1606 (T2-4) of the bladder were treated. @entity1 were divided into two groups. Group A included 17 @entity1 treated with @entity2834 systemic chemotherapy ( @entity1499 30 mg/m(2) and @entity5713 3 mg/m(2), day 1; and @entity900 70 mg/ m(2), day 2) repeated every 3 weeks for 3 courses, combined with intravesical BCG. Complete responders (CR) received maintenance intravesical BCG, while partial responders (PR) were subjected to transurethral bladder resection (TURB) or partial bladder resection. Group B included 16 @entity1 treated with maximal TURB followed by 2 @entity2834 courses and radiotherapy. RESULTS: Group A @entity1 have been followed-up for a period of 7 to 48 months (median 21.6 months). After completing the 2nd chemotherapy course, 2 @entity1 refused further treatment and were excluded from the group. On completing chemoimmunotherapy 11 (73%) @entity1 showed objective response (CR+PR) and preservation of the bladder was achieved. Four (27%) @entity1 were treatment failures. Group B @entity1 have been followed for a period of 9 to 47 months (median 27.5 months). On completing treatment 12 of 16 (75%) @entity1 showed an objective response with preservation of the bladder. Treatment failure was diagnosed in 4 (25%) @entity1 . The 2 groups differed significantly in terms of side-effects, which were more pronounced in Group B @entity1 . Of the late complications in Group B a serious problem was the development of severe radiation-induced @entity82 leading to microcystis and a cystectomy was indispensable in one of the @entity1 . CONCLUSION: The applied 2 approaches of combined organ-sparing treatment of invasive @entity150 seem equally effective. Future randomized studies are needed to define reliable criteria for @entity1 selection.

Organ-sparing treatment of invasive transitional cell XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'PATIENTS', 'patient'] @entity82 :: ('MESH:D005355', 'Disease') :: ['fibrosis'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity150 :: ('MESH:D001749', 'Disease') :: ['bladder carcinoma'] @entity1606 :: ('MESH:D002295', 'Disease') :: ['transitional cell carcinoma'] @entity2834 :: ('12305', 'Species') :: ['CMV'] @entity1499 :: ('MESH:D008727', 'Chemical') :: ['methotrexate'] @entity5713 :: ('MESH:D014747', 'Chemical') :: ['vinblastine']
@entity150 :: (MESH:D001749,Disease) :: ['bladder carcinoma']
